{"groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Pembrolizumab: Given IV\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Pharmacological Study: Correlative studies","id":"FG000","title":"Phase 2 Group I (Pembrolizumab)"},{"description":"Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Anetumab Ravtansine: Given IV\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Pembrolizumab: Given IV\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\>\n\n\\> Pharmacological Study: Correlative studies","id":"FG001","title":"Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab)"},{"description":"Anetumab Ravtansine Dose 6.5 mg/kg","id":"FG002","title":"Phase 1 Cohort Dose Level 1"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}